当前位置: X-MOL 学术Genet. Test. Mol. Biomark. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Experimental Study and Clinical Observation on the Improvement Effect of Lienal Polypeptide on Blood Toxicity and Immune Injury Induced by Radiotherapy.
Genetic Testing and Molecular Biomarkers ( IF 1.4 ) Pub Date : 2020-02-01 , DOI: 10.1089/gtmb.2019.0138
Alan Chu 1 , Rui Song 1 , Ge Hou 1 , Jinjin Yuan 1 , Cheng Wang 1 , Yu Yang 1 , Ning Qin 1 , Yaohe Liu 1 , Bing Liang 2 , Yan Zhang 3 , Zongwen Liu 1
Affiliation  

Aims: To investigate the immune and gastrointestinal functional effects of lienal polypeptide (LP) treatment in tumor-bearing mice and carcinoma patients receiving radiotherapy (RT), and to detect hematological indicators and T lymphocyte subsets. Methods: Tumor-bearing mice were randomly divided into five groups: the control group, the RT group, the RT+LP-L (1.7 mg/kg, low dosage of LP) group, the RT+LP-M (5.2 mg/kg, middle dosage of LP) group, and the RT+LP-H (10.4 mg/kg, high dosage of LP) group. In addition, carcinoma patients were randomly divided into two groups. The observation group was given LP during RT, and the control group was only treated with RT. We then compared the myelosuppression, gastrointestinal reactions, and clinical efficacy among groups. Results: In the animal experiments, compared with the control group, the number of leukocytes and lymphocytes of the mice in the "RT" group decreased (p < 0.05). Animals receiving LP evidenced a dose-response curve with regard to the number of leukocytes and lymphocytes that was proportional to the LP dose, increased (p < 0.05). Flow cytometric analyses showed that LP treatment of the mice increased the numbers of CD3+, and CD4+ T cells and theCD4+/CD8+ ratio. In our clinical study, the Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) criteria were used for measuring myelosuppression and gastrointestinal reactions. The RTOG/EORTC grade 3 or 4 inhibition rate of leukocytes, granulocytes, hemoglobin, platelets, and gastrointestinal toxic effects in the observation group were significantly lower than that in the control group (p < 0.05). Conclusion: LP can improve the hematopoietic and immune function of RT-treated mice and reduce the hematological and gastrointestinal toxicity of patients treated with RT and improve the quality of life.

中文翻译:

连体多肽改善放疗所致血液毒性和免疫损伤的实验研究和临床观察。

目的:研究在接受放疗(RT)的荷瘤小鼠和癌症患者中,血清多肽(LP)治疗对免疫和胃肠功能的影响,并检测血液学指标和T淋巴细胞亚群。方法:荷瘤小鼠随机分为5组:对照组,RT组,RT + LP-L(1.7 mg / kg,低剂量LP)组,RT + LP-M(5.2 mg / kg)。 kg,LP的中等剂量组和RT + LP-H(10.4 mg / kg,LP的高剂量)组。此外,将癌症患者随机分为两组。观察组在放疗期间给予LP,对照组仅接受放疗。然后,我们比较了各组之间的骨髓抑制,胃肠道反应和临床疗效。结果:在动物实验中,与对照组相比,“ RT”组小鼠的白细胞和淋巴细胞数量减少(p <0.05)。接受LP的动物表现出与LP剂量成比例的白细胞和淋巴细胞数量的剂量反应曲线增加(p <0.05)。流式细胞仪分析表明,LP处理小鼠增加了CD3 +和CD4 + T细胞的数量以及CD4 + / CD8 +的比例。在我们的临床研究中,放射治疗肿瘤学小组(RTOG)/欧洲癌症研究和治疗组织(EORTC)标准用于测量骨髓抑制和胃肠道反应。观察组对白细胞,粒细胞,血红蛋白,血小板和胃肠道毒性的RTOG / EORTC 3或4级抑制率显着低于对照组(p <0.05)。
更新日期:2020-02-01
down
wechat
bug